Amphastar Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Amphastar Pharmaceuticals has a total shareholder equity of $727.7M and total debt of $596.2M, which brings its debt-to-equity ratio to 81.9%. Its total assets and total liabilities are $1.5B and $817.5M respectively. Amphastar Pharmaceuticals's EBIT is $214.3M making its interest coverage ratio 7.9. It has cash and short-term investments of $250.5M.
Key information
81.9%
Debt to equity ratio
US$596.21m
Debt
| Interest coverage ratio | 7.9x |
| Cash | US$250.49m |
| Equity | US$727.68m |
| Total liabilities | US$817.50m |
| Total assets | US$1.55b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 29A's short term assets ($545.9M) exceed its short term liabilities ($159.0M).
Long Term Liabilities: 29A's short term assets ($545.9M) do not cover its long term liabilities ($658.5M).
Debt to Equity History and Analysis
Debt Level: 29A's net debt to equity ratio (47.5%) is considered high.
Reducing Debt: 29A's debt to equity ratio has increased from 10.2% to 81.9% over the past 5 years.
Debt Coverage: 29A's debt is well covered by operating cash flow (34.9%).
Interest Coverage: 29A's interest payments on its debt are well covered by EBIT (7.9x coverage).